Takahashi K, Uenishi N, Sanui M et al (2024) Clinical profile of patients with diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome in Japan: a multicenter retrospective cohort study. Acta Diabetol 61:117–126. https://doi.org/10.1007/s00592-023-02181-1

Article  PubMed  Google Scholar 

Dhatariya KK (2019) Defining and characterising diabetic ketoacidosis in adults. Diabetes Res Clin Pract. https://doi.org/10.1016/j.diabres.2019.107797

Article  PubMed  Google Scholar 

Benoit SR, Zhang Y, Geiss LS, et al (2018) Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality — United States, 2000–2014. MMWR Morb Mortal Wkly Rep 67:362–365. https://doi.org/10.15585/mmwr.mm6712a3

Romera I, Ampudia-Blasco FJ, Pérez A et al (2016) Eficacia y seguridad de empagliflozina en combinación con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2. Endocrinol Nutr 63:519–526. https://doi.org/10.1016/j.endonu.2016.06.003

Article  PubMed  Google Scholar 

Pujante P, Ares J, Maciá C, et al Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes Type 2. Medicina Clínica. https://doi.org/10.1016/j.medcli.2018.09.019

Palanca A, van Nes F, Pardo F et al (2022) Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with Type 1 diabetes: a european two-center experience. Diabetes Care 45:650–658. https://doi.org/10.2337/dc21-1584

Article  CAS  PubMed  Google Scholar 

Durán-Martínez M, Azriel S, Doulatram-Gamgaram VK et al (2024) Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: the Dapa-ON multicenter retrospective study. Diabetes Metab 50:101501. https://doi.org/10.1016/j.diabet.2023.101501

Article  CAS  PubMed  Google Scholar 

Colacci M, Fralick J, Odutayo A, Fralick M (2022) Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with Type 2 Diabetes: a systematic review and meta-analysis. Can J Diabetes 46:10-15.e2. https://doi.org/10.1016/j.jcjd.2021.04.006

Article  PubMed  Google Scholar 

Meyer EJ, Gabb G, Jesudason D (2018) SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care 41:e47–e49. https://doi.org/10.2337/dc17-1721

Article  CAS  PubMed  Google Scholar 

Palmer BF, Clegg DJ (2021) Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol

Hayes AG, Raven LM, Viardot A et al (2023) SGLT2 inhibitor-induced ketoacidosis in a patient without diabetes. Diabetes Care 47:e4–e5. https://doi.org/10.2337/dc23-1903

Article  Google Scholar 

Danne T, Garg S, Peters AL et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with Type 1 Diabetes treated with Sodium-Glucose Cotransporter (SGLT) inhibitors. Diabetes Care 42:1147–1154. https://doi.org/10.2337/dc18-2316

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolfsdorf JI, Ratner RE (2019) SGLT inhibitors for Type 1 Diabetes: proceed with extreme caution. Diabetes Care 42:991–993. https://doi.org/10.2337/dci19-0008

Article  CAS  PubMed  Google Scholar 

Savage MW, Dhatariya KK, Kilvert A et al (2011) Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med 28:508–515. https://doi.org/10.1111/j.1464-5491.2011.03246.x

Article  CAS  PubMed  Google Scholar 

Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA (2006) Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 29:2739–2748. https://doi.org/10.2337/dc06-9916

Article  CAS  PubMed  Google Scholar 

Rassen JA, Shelat AA, Myers J et al (2012) One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 21:69–80. https://doi.org/10.1002/pds.3263

Article  PubMed  Google Scholar 

Rothman KJ, Lash TL, Greenland S (2008) Modern epidemiology / Kenneth J. Rothman; Sander Greenland; Timothy L. Lash, 3rd. ed. Lippincott Williams & Wilkins, Philadelphia

Team RC (2013) R: A language and environment for statistical computing

Bernard Zinman, Christoph Wanner, Lachin John M et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720

Article  CAS  Google Scholar 

Bruce Neal, Vlado Perkovic, Mahaffey Kenneth W et al (2017) Canagliflozin and cardiovascular and renal events in Type 2 Diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925

Article  Google Scholar 

Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461. https://doi.org/10.1056/NEJMoa2107038

Article  CAS  PubMed  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303

Article  CAS  PubMed  Google Scholar 

Haidar A, Yale J-F, Lovblom LE et al (2021) Reducing the need for carbohydrate counting in Type 1 Diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: a randomized, controlled, non-inferiority, crossover pilot trial. Diabetes Obes Metab 23:1272–1281. https://doi.org/10.1111/dom.14335

Article  CAS  PubMed  Google Scholar 

Garcia-Tirado J, Farhy L, Nass R et al (2022) Automated insulin delivery with SGLT2i combination therapy in Type 1 Diabetes. Diabetes Technol Ther 24:461–470. https://doi.org/10.1089/dia.2021.0542

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Desai M, Ryan PB et al (2017) Incidence of diabetic ketoacidosis among patients with Type 2 Diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Res Clin Pract 128:83–90. https://doi.org/10.1016/j.diabres.2017.04.004

Article  CAS  PubMed  Google Scholar 

Haddadin R, Aboujamra D, Iraninezhad H (2023) Sodium-glucose cotransporter-2 inhibitor-induced euglycemic diabetic ketoacidosis in a Type 2 Diabetic patient. Cureus 15:e51184. https://doi.org/10.7759/cureus.51184

Article  PubMed  PubMed Central  Google Scholar 

Zhao Z, Zhao F, Zhang Y et al (2023) Risk factors of dapagliflozin-associated diabetic ketosis/ketoacidosis in patients with type 2 diabetes mellitus: a matched case-control study. Diabetes Res Clin Pract. https://doi.org/10.1016/j.diabres.2023.110236

Article  PubMed  Google Scholar 

Peters AL, Buschur EO, Buse JB et al (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:1687–1693. https://doi.org/10.2337/dc15-0843

Article  CAS  PubMed  PubMed Central  Google Scholar 

Danne T, Edelman S, Frias JP et al (2021) Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2. Diabetes Obes Metab 23:854–860. https://doi.org/10.1111/dom.14271

Article  CAS  PubMed  Google Scholar 

Siegmund T, Ampudia-Blasco FJ, Schnell O (2020) Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes. Diabetes Res Clin Pract. https://doi.org/10.1016/j.diabres.2020.108131

Article  PubMed  Google Scholar 

Boeder S, Davies MJ, McGill JB et al (2024) Beta-hydroxybutyrate levels and risk of diabetic ketoacidosis in adults with Type 1 Diabetes treated with sotagliflozin. Diabetes Technol Ther. https://doi.org/10.1089/dia.2023.0605

Article  PubMed  Google Scholar 

Halimi S, Vergès B (2014) Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 40:S28–S34. https://doi.org/10.1016/S1262-3636(14)72693-X

Article  CAS  PubMed  Google Scholar 

Ogawa W, Sakaguchi K (2016) Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 7:135–138. https://doi.org/10.1111/jdi.12401

Article  CAS  PubMed  Google Scholar 

Kibbey RG (2015) SGLT-2 inhibition and glucagon: cause for alarm? Trends Endocrinol Metab 26:337–338. h